These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2370328)

  • 1. Relation of application time to bioactivity of a potent topical glucocorticoid formulation.
    Stoughton RB; Wullich K
    J Am Acad Dermatol; 1990 Jun; 22(6 Pt 1):1038-41. PubMed ID: 2370328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrinsic potencies of novel thiol ester corticosteroids RS-85095 and RS-21314 as compared with clobetasol 17-propionate and fluocinonide.
    Ong JT; Poulsen BJ; Akers WA; Scholtz JR; Genter FC; Kertesz DJ
    Arch Dermatol; 1989 Dec; 125(12):1662-5. PubMed ID: 2589861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clobetasol propionate versus fluocinonide creams in psoriasis and eczema.
    Jegasothy B; Jacobson C; Levine N; Millikan L; Olsen E; Pinnell S; Cole G; Weinstein G; Porter M
    Int J Dermatol; 1985 Sep; 24(7):461-5. PubMed ID: 3902682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of topical application of clobetasol 17-propionate from various cream bases.
    Fang JY; Shen KL; Huang YB; Wu PC; Tsai YH
    Drug Dev Ind Pharm; 1999 Jan; 25(1):7-14. PubMed ID: 10028413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind, comparative clinical trials with halobetasol propionate cream in patients with atopic dermatitis.
    Yawalkar SJ; Schwerzmann L
    J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1163-6. PubMed ID: 1757610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability of clobetasol propionate-quantification of drug concentrations in the stratum corneum by dermatopharmacokinetics using tape stripping.
    Weigmann H; Lademann J; v Pelchrzim R; Sterry W; Hagemeister T; Molzahn R; Schaefer M; Lindscheid M; Schaefer H; Shah VP
    Skin Pharmacol Appl Skin Physiol; 1999; 12(1-2):46-53. PubMed ID: 10325583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clobetasol propionate ointment once daily versus fluocinonide ointment three times daily in psoriasis.
    Bickers D; Cornell R; Kamm AR; Bauman WE; Handler RM; Medansky RS; Sturm HM
    Int J Dermatol; 1988; 27(1):54-5. PubMed ID: 3278991
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of bullous pemphigoid with topical clobetasol propionate.
    Westerhof W
    J Am Acad Dermatol; 1989 Mar; 20(3):458-61. PubMed ID: 2645323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability of clobetasol propionate in different vehicles.
    Franz TJ; Lehman PA; Feldman SR; Spellman MC
    Skin Pharmacol Appl Skin Physiol; 2003; 16(4):212-6. PubMed ID: 12784060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo determination of the skin atrophy potential of the super-high-potency topical corticosteroid fluocinonide 0.1% cream compared with clobetasol propionate 0.05% cream and foam, and a vehicle.
    Gans EH; Sadiq I; Stoudemayer T; Stoudemayer M; Kligman AM
    J Drugs Dermatol; 2008 Jan; 7(1):28-32. PubMed ID: 18246695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adrenal suppression following low-dose topical clobetasol propionate.
    Ohman EM; Rogers S; Meenan FO; McKenna TJ
    J R Soc Med; 1987 Jul; 80(7):422-4. PubMed ID: 3656312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of different desoximetasone preparations compared to other topical corticosteroids in the vasoconstriction assay.
    Borelli C; Gassmueller J; Fluhr JW; Nietsch KH; Schinzel S; Korting HC
    Skin Pharmacol Physiol; 2008; 21(3):181-7. PubMed ID: 18523415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single-center, double-blind, randomized trial of the atrophogenic effects of fluocinonide cream 0.1% versus clobetasol propionate cream 0.05% in participants with corticosteroid-responsive dermatoses.
    Uliasz A; Zeichner J; Soung J; Wong V; Lebwohl M
    Cutis; 2008 Jun; 81(6):517-9. PubMed ID: 18666395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of three class I topical synthetic corticosteroids, fluocinonide 0.1% cream, clobetasol 0.05% cream and halobetasol 0.05% cream: a Scholtz-Dumas bioassay comparison.
    Lee CS; Koo J
    J Drugs Dermatol; 2009 Aug; 8(8):751-5. PubMed ID: 19663113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Halobetasol Propionate Lotion, 0.05% Provides Superior Hydration Compared to Halobetasol Propionate Cream, 0.05% in a Double-Blinded Study of Occlusivity and Hydration.
    Grove G; Zerweck C; Houser T; Andrasfay A; Gauthier B; Holland C; Piacquadio D
    J Drugs Dermatol; 2017 Feb; 16(2):140-144. PubMed ID: 28300856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream.
    Korting HC; Vieluf D; Kerscher M
    Eur J Clin Pharmacol; 1992; 42(2):159-61. PubMed ID: 1618247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of a corticosteroid cream for immediate reduction in the clinical signs of acne vulgaris.
    Hull SM; Cunliffe WJ
    Acta Derm Venereol; 1989; 69(5):452-3. PubMed ID: 2572120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of topically applied clobetasol-17-propionate on histamine release in human skin.
    Ståhle M; Hägermark O
    Acta Derm Venereol; 1984; 64(3):239-42. PubMed ID: 6204486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RU 486 inhibits peripheral effects of glucocorticoids in humans.
    Gaillard RC; Poffet D; Riondel AM; Saurat JH
    J Clin Endocrinol Metab; 1985 Dec; 61(6):1009-11. PubMed ID: 4055982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical retinoic acid does not alter the vasoconstrictive properties of topical corticosteroids in humans.
    Schmied C; Saurat JH
    Dermatologica; 1991; 182(2):107-11. PubMed ID: 2050230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.